It is scientific expertise like this that makes me increasingly concerned that some smart BigPharma is going to buyout MNTA on the cheap. Not so much for its obvious money making abilities (in m-enox and m-copax), but for the raw analytic talent they possess.
They provided abilities beyond BigPharma (and even the FDA) in the heparin contamination fiasco. MNTA's abilty to assay for unwanted, potentially dangerous sugars on CHO-produced FOB's could be a very inexpensive insurance policy for a big firm.
Hope we are able to stay independent at least until the obvious (if unrecognized in the stock price) strengths of sole generic in both m-enox and m-Copax are finally realized.
Market Data 
Markets 
AI
